{
    "clinical_study": {
        "@rank": "148206", 
        "arm_group": [
            {
                "arm_group_label": "OPTIVE FUSION\u2122", 
                "arm_group_type": "Active Comparator", 
                "description": "1-2 drops OPTIVE FUSION\u2122 (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months."
            }, 
            {
                "arm_group_label": "VISMED\u00ae Multi", 
                "arm_group_type": "Active Comparator", 
                "description": "1-2 drops VISMED\u00ae Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of OPTIVE FUSION\u2122 compared to VISMED\u00ae Multi\n      for the management of dry eye."
        }, 
        "brief_title": "A Safety and Efficacy Study of OPTIVE FUSION\u2122 With VISMED\u00ae Multi for the Management of Dry Eye", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Dry Eye Syndromes", 
            "Keratoconjunctivitis Sicca"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca", 
                "Keratoconjunctivitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Use of artificial tears for dry eye in both eyes for at least 3 months\n\n          -  Use of preservative-free artificial tears at least twice daily for 2 weeks;\n\n        Exclusion Criteria:\n\n          -  Cataract, laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy\n             (PRK) surgery in the last 12 months\n\n          -  Use of punctal plugs or contact lenses in the last month\n\n          -  Active ocular allergy within last 2 years\n\n          -  Best corrected visual acuity (BCVA) less than 20/200 in either eye"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117687", 
            "org_study_id": "MAF-AGN-OPH-DE-016"
        }, 
        "intervention": [
            {
                "arm_group_label": "OPTIVE FUSION\u2122", 
                "description": "1-2 drops OPTIVE FUSION\u2122 (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.", 
                "intervention_name": "carboxymethylcellulose 0.5%/glycerin 0.9%", 
                "intervention_type": "Drug", 
                "other_name": "OPTIVE FUSION\u2122"
            }, 
            {
                "arm_group_label": "VISMED\u00ae Multi", 
                "description": "1-2 drops VISMED\u00ae Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.", 
                "intervention_name": "sodium hyaluronate 0.18%", 
                "intervention_type": "Drug", 
                "other_name": "VISMED\u00ae Multi"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboxymethylcellulose Sodium", 
                "Glycerol", 
                "Hyaluronic Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aix-en-Provence", 
                        "country": "France"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Institutional Ethical Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Global Ocular Staining Score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Day 35"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117687"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change from Baseline in Ocular Surface Disease Index\u00a9 (OSDI) Score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Day 35"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}